# Melanotans

Sonoran UV Biology · Clinical & Regulatory Field Report

**Directory:** [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Scenesse](/afamelanotide-scenesse) · [Vyleesi](/bremelanotide-vyleesi) · [Imcivree](/setmelanotide-imcivree) · [Online Market](/melanotan-online-market) · [Case Reports](/case-reports-and-safety) · [Regulators](/regulatory-warnings) · [References](/references) · [About](/about)

**Prescription Medicine · Cyclic 7-Amino-Acid Free Acid (-OH) · Nonselective MCR Agonist** · Dispatch 04 · Bremelanotide (Vyleesi)

---

[Melanotans](/) / Bremelanotide (Vyleesi)

# Bremelanotide (Vyleesi): Swapping one terminal group yielded a prescription melanocortin drug

Only one C-terminal functional group separates prescription bremelanotide from Melanotan II—and FDA's June 2019 prescribing label documents the clinical tradeoffs of a nonselective melanocortin agonist.

**Field Record 06 · Evening Alcove:** FDA's [June 2019 prescribing label (Revised: 6/2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) restricts Vyleesi to premenopausal women with acquired, generalized hypoactive sexual desire disorder.

## One functional group from Melanotan II

**Bremelanotide (Vyleesi)**, studied under the code `PT-141`, is the closest structural relative to Melanotan II in prescription medicine. FDA's [June 2019 label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) describes bremelanotide as a synthetic cyclic heptapeptide (free-base molecular weight **1025.2**) with the structure `Ac-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys-OH)`. Compared directly with [Melanotan II](https://pubmed.ncbi.nlm.nih.gov/8637402/) (`Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10-NH2`), every amino acid and the cyclic lactam ring match, except bremelanotide replaces the C-terminal amide (`-NH2`) with a free carboxylic acid (`-OH`). As King and colleagues wrote in 2007, [PT-141 is the deaminated carboxylate derivative and likely metabolite of Melanotan II](https://pmc.ncbi.nlm.nih.gov/articles/PMC2694735/).

**Figure 5 · Architectural Comparison of Four Melanocortin Peptides.** All three Arizona-lineage molecules share the modified `His–D-Phe–Arg–Trp` core; replacing Melanotan II's terminal amide (`-NH2`) with a free acid (`-OH`) yields bremelanotide. Sources: [Dorr (1996)](https://pubmed.ncbi.nlm.nih.gov/8637402/); [FDA Scenesse Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf); [FDA Vyleesi Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf); [FDA Imcivree Label (03/2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf).

## Clinical development and dated June 2019 FDA label text

After University of Arizona clinical trials documented Melanotan II's erectogenic activity ([Dorr et al., 1996](https://pubmed.ncbi.nlm.nih.gov/8637402/); [Wessells et al., 1998](https://pubmed.ncbi.nlm.nih.gov/9679884/)), Palatin Technologies tested `PT-141` in male sexual dysfunction ([Hadley & Dorr, 2006](https://pubmed.ncbi.nlm.nih.gov/16412534/)). In [preclinical studies, PT-141 induced erections in rats and nonhuman primates. Researchers measured hypothalamic neuronal activation in rats](https://pubmed.ncbi.nlm.nih.gov/12851303/). In an early [Phase 1 randomized, double-blind, placebo-controlled trial of 24 healthy men without erectile dysfunction](https://pmc.ncbi.nlm.nih.gov/articles/PMC2694735/), PT-141 increased duration of rigid erections on RigiScan monitoring to 140 minutes compared to 22 minutes in the placebo group.

Commercial development later centered on women's sexual health. FDA's [NDA 210557 approval letter (dated 06/21/2019)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf) and [prescribing information (Revised: 6/2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) state: "VYLEESI is a melanocortin receptor agonist indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance." Under Limitations of Use, the June 2019 label adds: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men." "VYLEESI is not indicated to enhance sexual performance."

## Pharmacology and pharmacokinetics

FDA's [June 2019 label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) states that bremelanotide "nonselectively activates several receptor subtypes with the following order of potency: MC1R, MC4R, MC3R, MC5R, MC2R," adding that at therapeutic dose levels binding to `MC1R` and `MC4R` is most relevant and "The mechanism by which VYLEESI improves HSDD in women is unknown." Following a single subcutaneous administration, absolute bioavailability was about 100%, median `Tmax` was approximately **1.0 hour** (range 0.5–1.0 hours), mean terminal half-life was **approximately 2.7 hours** (range 1.9–4.0 hours), and **mean apparent clearance (`CL/F`) was 6.5 ± 1.0 L/hr** ([FDA Label, Revised: 6/2019](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf)).

## RECONNECT Phase 3 evidence: Modest gains, null SSEs, high dropouts

Two identical 24-week randomized, double-blind, placebo-controlled, multicenter trials—**RECONNECT** (NCT02333071 Study 301 and NCT02338960 Study 302), funded by Palatin Technologies and AMAG Pharmaceuticals ([Kingsberg et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31599840/))—randomized **1,267 premenopausal women** (mean age 39 years; 85.6% white; 96.6% U.S. sites). Of those randomized, **1,247 entered the safety population** (*n* = 627 Vyleesi, *n* = 620 placebo; [FDA Label Table 1](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf)) and **1,202 entered the modified intent-to-treat (MITT) efficacy population** ([Kingsberg et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31599840/); Study 1: *N* = 290 active vs. *N* = 316 placebo; Study 2: *N* = 282 active vs. *N* = 314 placebo).

### RECONNECT Phase 3 Efficacy & Discontinuation Summary (MITT Efficacy Population, *n* = 1,202)

| Measure (24-Week Double-Blind Period) | Study 1 / 301 | Study 2 / 302 | Primary Source |
|---|---|---|---|
| FSFI Desire Domain vs. placebo (co-primary; [1.2–6.0 scale](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf)) | +0.30 (*P* < 0.001) | +0.42 (*P* < 0.001) | [Kingsberg (2019)](https://pubmed.ncbi.nlm.nih.gov/31599840/); [FDA Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) |
| FSDS-DAO Q13 distress vs. placebo (co-primary; [0–4 scale](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf)) | −0.37 (*P* < 0.001) | −0.29 (*P* = 0.005) | [Kingsberg (2019)](https://pubmed.ncbi.nlm.nih.gov/31599840/); [FDA Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) |
| Satisfying sexual events (SSEs, secondary; mean change) | 0.0 vs. −0.1 (*p* = 0.76) | 0.0 vs. 0.0 (*p* = 0.70) | [FDA Label (6/2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) |
| Premature trial discontinuation (Vyleesi vs. placebo, MITT) | 40% vs. 13% | 39% vs. 25% | [FDA Label (6/2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) |

Both studies achieved statistical significance on co-primary desire and distress scales (integrated differences +0.35 and −0.33, both *P* < 0.001, [Kingsberg et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31599840/)). Yet [FDA's June 2019 label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) records two major counterweights: there was no significant difference between groups in the secondary endpoint of satisfying sexual events (*p* = 0.76; *p* = 0.70), and premature discontinuation in the MITT population reached **40% vs. 13%** in Study 1 and **39% vs. 25%** in Study 2—with **18%** of the safety set stopping due to adverse reactions versus **2%** on placebo.

## The spillover ledger: Blood pressure, nausea, and focal pigment

- **Cardiovascular contraindication and blood pressure:** FDA's [June 2019 label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) states: "VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease." Clinical studies recorded maximal transient increases of **6 mmHg systolic** and **3 mmHg diastolic blood pressure** peaking 2 to 4 hours post-dose, with heart-rate reductions up to **5 beats per minute**, usually returning to baseline within 12 hours. In an open-label ambulatory monitoring study of **127 premenopausal women** given daily Vyleesi, daytime blood pressure rose by a mean of **1.9 mmHg systolic** and **1.7 mmHg diastolic** after 8 days.
- **Nausea, flushing, and gastric-emptying interaction:** In the safety population (*n* = 627 active vs. *n* = 620 placebo; [FDA Label Table 1](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf)), nausea occurred in **40.0% vs. 1.3%** (requiring anti-emetics in **13%** and causing discontinuation in **8%**), alongside flushing (20.3% vs. 0.3%), injection-site reactions (13.2% vs. 8.4%), headache (11.3% vs. 1.9%), and vomiting (4.8% vs. 0.2%). Regarding slowed gastric emptying, FDA's [June 2019 label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) states: "As VYLEESI may significantly decrease the systemic exposure of orally-administered naltrexone, patients should avoid using VYLEESI with an orally administered naltrexone-containing product that is intended to treat alcohol and opioid addiction due to the severe consequence of naltrexone treatment failure." One acute hepatitis case occurred in an uncontrolled extension after 10 doses over one year (liver tests normalized 4 months after stopping; no broader hepatotoxicity signal appeared).
- **MC1R pigment spillover:** In intermittent Phase 3 trials, [focal hyperpigmentation involving the face, gingiva, and breasts occurred in 1% of treated patients versus 0% on placebo](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf). In a separate daily-dosing study, [**38%** developed focal hyperpigmentation after 8 days, and, among those who continued for 8 more consecutive days, an additional **14%** developed new focal pigment changes](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf)—more common in patients with dark skin, with resolution not confirmed in all patients after stopping.

### Toxicology and mandatory FDA postmarketing studies
Two-year carcinogenicity studies in rats (intranasal) and mice (subcutaneous) found [no significant increases in tumor incidence](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf), whereas daily subcutaneous exposure in pregnant dogs at 16 times or higher the maximum recommended human exposure (AUC) caused fetal harm. FDA's [June 21, 2019 approval letter](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf) required a pregnancy safety study alongside a lactation trial (`3635-3`) measuring breast-milk drug levels and infant outcomes.

---

## Prescription Dossier · Vyleesi

- **Generic / Brand Name:** Bremelanotide (Vyleesi) · formerly `PT-141`
- **Dated Agency Records:** FDA `NDA 210557` approval letter (June 21, 2019) & prescribing label (Revised: 6/2019)
- **Chemical Identity:** Cyclic 7-aa free acid (`-OH`, `MW 1025.2`); deaminated derivative of Melanotan II (`-NH2`)
- **Receptor Order & PK:** Nonselective: `MC1R, MC4R, MC3R, MC5R, MC2R` · terminal half-life ~2.7 h; mean apparent clearance `CL/F` 6.5 ± 1.0 L/hr
- **Pivotal Trial Sets:** RECONNECT 301 & 302: 1,267 randomized; 1,247 safety (627 vs. 620); 1,202 MITT efficacy
- **Label Safety Flags:** Uncontrolled hypertension/CVD contraindication; 40.0% nausea; 38% 8-day daily focal hyperpigmentation; oral naltrexone interaction noted in June 2019 FDA label

### Compare Other Dispatches
- [03. Afamelanotide (Scenesse)](/afamelanotide-scenesse)
- [05. Setmelanotide (Imcivree)](/setmelanotide-imcivree)
- [07. MT-II Case Reports & Safety](/case-reports-and-safety)
- [08. Regulatory Records From Six Jurisdictions](/regulatory-warnings)

- Previous Dispatch · 03: [Afamelanotide (Scenesse)](/afamelanotide-scenesse)
- Next Dispatch · 05: [Setmelanotide (Imcivree)](/setmelanotide-imcivree)

---

**Melanotans** is an independent educational pharmacology field report on melanocortin receptor biology, prescription medicines afamelanotide (Scenesse), bremelanotide (Vyleesi), and setmelanotide (Imcivree), and online products sold as Melanotan I and II—not a laboratory, manufacturer, clinic, pharmacy, telehealth service, or seller, and never medical advice.

- Plain-text edition: [bremelanotide-vyleesi.md](/bremelanotide-vyleesi.md) · Full bibliography: [Primary Source Ledger](/references)
- Pathway & Prescription Medicines: [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Afamelanotide (Scenesse)](/afamelanotide-scenesse) · [Bremelanotide (Vyleesi)](/bremelanotide-vyleesi) · [Setmelanotide (Imcivree)](/setmelanotide-imcivree)
- Online Market, Safety & Charter: [Online Market & Lab Assays](/melanotan-online-market) · [Case Reports & Safety](/case-reports-and-safety) · [Regulatory Warnings](/regulatory-warnings) · [References](/references) · [About](/about) · [Contact](/contact)
